Loading...
XNASCRSP
Market cap3.48bUSD
Dec 24, Last price  
40.80USD
1D
0.79%
1Q
-11.15%
Jan 2017
101.38%
IPO
192.68%
Name

CRISPR Therapeutics AG

Chart & Performance

D1W1MN
XNAS:CRSP chart
P/E
P/S
9.38
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
10.56%
Rev. gr., 5y
160.00%
Revenues
371m
+85,038.99%
0247,0005,164,00040,997,0003,124,000289,590,000543,000913,081,000436,000371,206,000
Net income
-154m
L-76.37%
-6,800,000-25,828,000-23,202,000-68,357,000-164,981,00066,858,000-348,865,000377,661,000-650,175,000-153,610,000
CFO
-260m
L-47.48%
-4,793,00059,428,000-55,310,000-70,097,000-96,239,00056,677,000-238,366,000538,972,000-495,741,000-260,375,000
Earnings
Feb 19, 2025

Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
IPO date
Oct 19, 2016
Employees
458
Domiciled in
CH
Incorporated in
CH

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
371,206
85,038.99%
436
-99.95%
913,081
168,054.88%
Cost of revenue
593,744
674,359
559,388
Unusual Expense (Income)
NOPBT
(222,538)
(673,923)
353,693
NOPBT Margin
38.74%
Operating Taxes
2,888
(325)
1,870
Tax Rate
0.53%
NOPAT
(225,426)
(673,598)
351,823
Net income
(153,610)
-76.37%
(650,175)
-272.16%
377,661
-208.25%
Dividends
Dividend yield
Proceeds from repurchase of equity
32,721
38,592
250,945
BB yield
-0.66%
-1.22%
-4.12%
Debt
Debt current
31,250
15,842
12,158
Long-term debt
461,639
472,200
437,902
Deferred revenue
14,012
12,323
12,323
Other long-term liabilities
958
5,969
7,339
Net debt
(1,202,776)
(1,380,406)
(1,945,982)
Cash flow
Cash from operating activities
(260,375)
(495,741)
538,972
CAPEX
(9,470)
(37,188)
(81,705)
Cash from investing activities
374,647
(258,655)
(1,035,430)
Cash from financing activities
62,664
38,592
250,945
FCF
(348,092)
(682,118)
132,813
Balance
Cash
1,693,692
1,815,318
2,379,129
Long term investments
1,973
53,130
16,913
Excess cash
1,677,105
1,868,426
2,350,388
Stockholders' equity
(995,290)
(859,296)
(198,591)
Invested Capital
3,147,320
2,996,953
2,842,019
ROIC
13.67%
ROCE
13.38%
EV
Common stock shares outstanding
79,221
77,747
80,393
Price
62.60
54.00%
40.65
-46.36%
75.78
-50.51%
Market cap
4,959,230
56.92%
3,160,398
-48.12%
6,092,219
-39.67%
EV
3,756,454
1,779,992
4,146,237
EBITDA
(202,701)
(649,751)
371,646
EV/EBITDA
11.16
Interest
46,833
Interest/NOPBT